Fused polypeptide with DEF induces apoptosis of lung adenocarcinoma cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer research continuously seeks novel therapeutic agents.
• Peptides offer potential for targeted drug delivery and therapeutic effects.
• Understanding peptide-cell interactions is crucial for developing new cancer treatments.

Purpose of the Study:

• To investigate the antitumor effects of a novel fused polypeptide, TAT-DV1-DEF, containing peptide DEF.
• To analyze the mechanism by which TAT-DV1-DEF affects tumor cell growth and viability.
• To determine the specificity of TAT-DV1-DEF's action on cancer cells versus normal cells.

Main Methods:

• Synthesis and design of the fused polypeptide TAT-DV1-DEF.
• Cell viability assays (Cell Counting Kit-8) on lung adenocarcinoma (GLC-82) and human embryonic kidney (HEK-293) cell lines.
• Laser confocal microscopy for polypeptide localization.
• Flow cytometry for transfection efficiency.
• Fluorescence microscopy with DAPI staining for nuclear morphology analysis.
• Western blotting to evaluate apoptosis-related protein expression and signaling pathways.

Main Results:

• TAT-DV1-DEF significantly inhibited the growth of GLC-82 lung adenocarcinoma cells.
• No significant inhibition was observed in the normal HEK-293 cell line, indicating specificity.
• Polypeptides were primarily localized in the cytoplasm and mitochondria.
• High transfection efficiency (approx. 99%) was achieved in both cell types.
• Apoptotic nuclear morphology was observed, and Western blot analysis confirmed apoptosis induction.
• The growth inhibition mechanism was determined to be apoptosis-dependent.

Conclusions:

• The fused polypeptide TAT-DV1-DEF exhibits significant antitumor activity against lung adenocarcinoma cells.
• Peptide DEF, delivered via the TAT-DV1-DEF construct, induces apoptosis in cancer cells.
• The findings suggest that peptide DEF has potential as a therapeutic agent for lung adenocarcinoma.